Permissive Blood Pressure Targets in Pediatric Critical Care: The PRESSURE Randomized Clinical Trial
In brief
Permissive blood pressure target cuts drug doses 37.5% but not ventilation or survival
In a trial of 1,900 critically ill children receiving ventilation and blood pressure drugs, a lower target reduced median drug dose by 37.5% but did not significantly change the combined outcome of death and ventilation duration at 30 days. Most other outcomes were also similar; whether the modestly shorter PICU stay among survivors matters clinically remains unclear.
- Journal
- JAMA (Q1)
- Published
- 28 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- David P Inwald, Emma Laing, Julia M Broomhall, Tommaso Viola, Carly Au, Alanna Brown, et al.
- PMID
- 42806496
- DOI
- 10.1001/jama.2026.19747
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (top studies of the week, 1 November 2026): Pediatric ICU randomized trial of vasopressor and blood-pressure targets
- Picked for Radiation Oncology (top studies of the week, 4 October 2026): Not relevant to radiation oncology
- Picked for Surgical Oncology (top studies of the week, 4 October 2026): High-quality evidence in a top journal
- Picked for Pediatric Surgery (top studies of the week, 4 October 2026): Randomized trial, MAP targets in critically ill children
- Picked for Bariatric and Metabolic Surgery (top studies of the week, 4 October 2026): High-quality evidence in a top journal
- Picked for Plastic and Reconstructive Surgery (top studies of the week, 4 October 2026): Permissive blood pressure targets in pediatric ICU, critical care
- Picked for Pediatrics and Child Health (top studies of the week, 4 October 2026): Multicenter RCT, permissive MAP targets in PICU
- Picked for Spine Surgery (top studies of the week, 4 October 2026): High-quality evidence in a top journal
Abstract
IMPORTANCE: Vasoactive drugs are often given to critically ill children to treat hypotension. However, optimal mean arterial pressure (MAP) targets are unknown. OBJECTIVE: To evaluate whether adopting a permissive MAP target, and thereby potentially reducing exposure to vasoactive drugs, improves outcomes in hypotensive critically ill children. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, unblinded, pragmatic randomized clinical trial was conducted in 23 pediatric intensive care units (PICUs) in 3 countries. Critically ill children receiving invasive ventilation and vasoactive drugs for hypotension were enrolled between November 2021 and May 2026. Follow-up to the 30-day outcome was completed in June 2026. INTERVENTIONS: Patients randomized to the intervention (n = 957) were assigned a permissive MAP target greater than the fifth percentile for age. Patients in the control group (n = 943) received usual care with MAP target set by the attending physician. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of mortality and duration of invasive ventilation at 30 days. Secondary outcomes included mortality at PICU discharge, time to cessation of invasive ventilation, receipt and duration of kidney replacement therapy in PICU at 30 days, and length of PICU and hospital stay. RESULTS: Of 1900 randomized patients, 910 in the permissive MAP target group and 904 in the usual care group were included for analysis of the primary outcome. Participants had a median (IQR) age of 4 (0-10) years and 44.8% were female; baseline characteristics were similar between the groups. Median (IQR) MAP while receiving vasoactive drugs was 58 (51-63) mm Hg in the permissive MAP target group and 61 (54-67) mm Hg in the usual care group. A permissive MAP target led to a 37.5% reduction in median norepinephrine-equivalent total dose compared with the usual care group. There was no significant difference between the groups in the primary outcome (probabilistic index, 0.52 [95% CI, 0.49-0.54]; P = .23). Six of the 7 secondary outcomes were similar between the groups, except median (IQR) PICU length of stay was significantly shorter in survivors in the permissive MAP target vs usual care group (159 [79-286] vs 166 [92-319] hours); probabilistic index, 0.53 [95% CI, 0.50-0.56]). Receipt of kidney replacement therapy and adverse events did not differ between the groups. CONCLUSIONS AND RELEVANCE: Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.